id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-024076-q9fw7ch1	Manga, Pravin	Should ACE Inhibitors and Angiotensin Receptor Blockers Be Withdrawn in the Current Setting of COVID-19 Infection?	2020-04-17		.txt	text/plain	1862	90	41	The reports urging caution in the use of ACE inhibitors and ARBs for hypertension, diabetes and cardiovascular disease are based on laboratory data which found that SARS-CoV and COVID-19 virus binds to ACE 2 receptor which is found in the epithelial cells of the lung, kidney, intestine and blood vessels. Thus, a clear causal relationship between those with cardiovascular disease, hypertension, heart failure with reduced ejection fraction (HFrEF), and diabetes with chronic kidney disease (DCKD) on ACE inhibitors or ARB treatment and an increased risk of COVID-19 does not exist. In South Africa, hypertension, HFrEF and diabetes are common non-communicable diseases, and a significant proportion of patients are being treated with generic versions of ACE inhibitors or ARBs. There is extremely strong scientific evidence for the benefit of RAAS inhibition in patients with cardiovascular disease.	./cache/cord-024076-q9fw7ch1.txt	./txt/cord-024076-q9fw7ch1.txt